University of Ioannina
Relationship of vitamin D with cardiovascular disease risk factors in adults and adolescents and possible impact on its metabolism from the use of lipid-lowering medication
Abstract
dc:descriptionBackground: Hypovitaminosis D has been associated with various cardiovascular disease CVD risk factors beginning in childhood/adolescence which manifest later in adulthood. Also statins may affect serum VitD levels, but there are insufficient data on the effect of other hypolipidemic drugs.Aims & Methods: The present study consists of 2 parts: Aims & Methods of cross-sectional study:Determination of serum 25(OH)VitD levels in Greek a) adults with Metabolic Syndrome (MetS) (N=52) and b) adolescents with obesity (N=69) and corresponding controls (58 adults, 34 adolescents). Investigation of the possible correlation between VitD levels and MetS diagnostic criteria and other biochemical parameters. Aims & Methods of prospective study: A) Assessment of the effect of hypolipidemic drugs on 25(OH)VitD serum levels in adult patients with dyslipidemia, at the beginning and 3 months after the start of treatment, based on 3 treatment protocols. B) Assessment of the effect of cholecalciferol (VitD3) administration on metabolic parameters in adults with MetS, randomized to apply either only healthy-dietary guidelines (N=25) or to receive 2000 IU VitD/day pos along with healthy-dietary guidelines (N=25), and in adolescents with obesity (BMI=35.0±7.9) and VitD deficiency (25(OH)VitD <20 ng/mL) (N=15) who received 2000 IU VitD/day pos along with healthy-dietary guidelines and were re-assessed 3 months later. Results:Results of the cross-sectional study: a) Adults with MetS had significantly lower serum 25(OH)VitD levels than controls [11.8 (0.6-48.3) ng/mL vs 17.2 (4.8-62.4) ng/mL, p=0.027]. In adults with MetS, univariate regression analysis showed that serum 25(OH)VitD levels correlated negatively with triglycerides, but not with other diagnostic criteria of MetS. In addition, 25(OH)VitD had a negative correlation with sdLDL-C and PTH levels, but not with LDL size, Lp-PLA2 activity and hsCRP. However, stepwise multivariate linear regression analysis showed that sdLDL-C levels were significantly affected only by triglyceride levels and not by 25(OH)VitD levels. b) Adolescents with obesity had lower serum 25(OH)VitD levels than normal-weight controls [12.0 (3.0-36.0) versus 34.0 (10.0-69.0) ng/mL respectively, p = 0.000]. In obese adolescents, serum 25(OH)VitD levels were found to be negatively correlated with serum leptin levels, independently of BMI. Results of the prospective study: A.i) Three months after drug treatment of adults with mixed dyslipidemia, serum 25(OH)VitD levels increased significantly in all 3 treatment groups: in the group receiving rosuvastatin 40 mg they increased by 53%, in group receiving rosuvastatin 10 mg plus phenofibrate by 64%, and in the group receiving rosuvastatin 10 mg plus omega-3 fatty acids by 61%. Increases in serum 25(OH)VitD levels were comparable in all 3 treatment groups. A.ii) Three months after drug treatment of adults with primary hypercholesterolemia, serum 25(OH)VitD levels increased significantly in both groups: in the recipients of simvastatin/ezetimibe 10/10 mg they increased by 36.7%, while in the group receiving simvastatin 40 mg by 79.1%. The increase in 25(OH)VitD levels was significantly higher in the simvastatin 40 mg group compared to that in simvastatin/ezetimibe 10/10 mg group. A.iii) Three months after the modification of medication in adults with mixed dyslipidemia who had not achieved the therapeutic goals with a conventional statin dose, serum 25(OH)VitD levels did not change significantly in all 3 treatment groups: in both groups receiving rosuvastatin 40 mg and rosuvastatin 10 mg plus nicotinic acid/laropiprant, a tendency to decrease was observed in 25(OH)VitD serum levels (-4.7% and -14.8%, respectively), which was not statistically significant. In the group that received rosuvastatin 10 mg plus phenofibrate an increase in 25(OH)VitD serum levels (+13%) was found, which was also statistically non-significant. The above changes in serum 25(OH)VitD levels did not differ statistically significantly between the 3 groups. B.i) In adults with MetS who received pos VitD supplementation, 25(OH)VitD levels increased by 91%, while those who did not receive VitD showed a statistically non-significant increase of 30%. In the group that received VitD, systolic BP decreased by 3.7%, while in the group that did not receive VitD it decreased by only 1.5% (p=NS in both). In the group that received VitD, the increase in 25(OH)VitD was significantly associated with a decrease in systolic BP Also, the urine isoprostane levels decreased significantly by 22.7% in the group receiving pos VitD, while a downward trend of 14.4% was found in the group that did not receive VitD, but it was not statistically significant. However, the reduction in urine isoprostane levels did not differ significantly between the 2 groups. B.ii) In adolescents with obesity and VitD insufficiency who received pos VitD, 25(OH)VitD levels increased significantly by 88.4%. At the same time, significant reductions were found in HbA1c and leptin levels, while LDL-C levels increased. Conclusions: Adults with MetS had significantly lower 25(OH)VitD levels compared with those without MetS. VitD deficiency was also more prevalent among Greek adolescents with obesity compared with controls. In adults with MetS 25(OH)VitD levels were inversely associated with triglycerides. In adolescents with obesity 25(OH)VitD was inversely associated with leptin. VitD supplementation plus dietary intervention in adults with MetS was not associated with any significant change in classic and emerging CVD risk factors, compared with dietary intervention alone. VitD supplementation in adolescents with obesity and hypovitaminosis D effectively increased their 25(OH)VitD levels and was associated with marginal decreases in HbA1c and leptin as well as an increase in LDL-C levels. Also, unlike rosuvastatin and simvastatin other lipid-lowering drugs like ezetimibe, fenofibrate, omega-3 fatty acids and nicotinic acid seem to have minimal if any effect on 25(OH)VitD serum concentrations in patients with dyslipidemia.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Makariou, Stefania
- Μακαρίου, Στεφανία
Subjects
dc:subject × 14Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48180